Gerwin Sandker studied Biomedical Sciences at the Radboud University in Nijmegen. He graduated in Toxicology with minors in Human Pathobiology and Epidemiology. The subject of his master thesis was ‘Evaluation of the cellular characteristics of the LewisY antigen-antibody system for the use in tumor targeting’. In 2018 he started his PhD-project at the NucMed group at the department of Medical Imaging. His PhD project focuses on innovative imaging approaches to study immunotherapies, their clinical effects, and their targets within the tumor microenvironment in a non-invasive manner. Novel tumor targeting agents and cell-labeling approaches are being developed and analyzed in vitro and in vivo in animal models for cancer. He is supervised by Sandra Heskamp and Erik Aarntzen.